Cleveland Clinic Cancer Center (Taussig) Outcomes
Leukemia & Myeloid Disorders
A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients With Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/Mutations)
2015-2021
Tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Many older patients (pts) are not good candidates for intensive chemotherapy and are treated with TKIs plus corticosteroids or low intensity chemotherapy. Although the remission rates with this approach have been high, the median disease-free survival (DFS) has been short. Therefore, novel treatment strategies are needed. This trial evaluated the feasibility of combining the TKI dasatinib with prednisone and blinatumomab in older pts with Ph+ ALL.
Three-Year Disease-Free Survival for Patients Receiving TKI Dasatinib With Prednisone and Blinatumomab
2015-2021
The median follow up for patients who are alive is 1.7 years.
Three-Year Overall Survival for Patients Receiving TKI Dasatinib With Prednisone and Blinatumomab
2015-2021
Kaplan-Meier 3-year estimates of overall survival and disease-free survival are 85% (95% CI 58%-95%) and 80% (95% CI 55%-92%), respectively.
This trial demonstrates the feasibility of combining dasatinib and blinatumomab in Ph+ ALL. In addition, with 1.7 years of follow up, outcomes are encouraging with high estimated 3-year DFS and OS. Longer follow up is needed to determine the durability of these results.
